JOINT BOARD FOR ENROLLMENT OF ACTUARIES

20 CFR Part 903

Privacy Act of 1974; Implementation

AGENCY: Joint Board for the Enrollment of Actuaries.

ACTION: Direct final rule.

SUMMARY: In accordance with the requirements of the Privacy Act of 1974, as amended, the Joint Board for the Enrollment of Actuaries (Joint Board) is amending the requirements regarding access to records to revise the listing of the Joint Board’s systems of records for which the Joint Board has claimed exemptions, under section (k)(2) of the Privacy Act, from certain of the Privacy Act’s provisions, to revise language that incorrectly implies that the Joint Board has yet to seek such exemptions or that incorrectly implies that the Joint Board’s claims for exemption are still pending, and to correct internal references.

DATES: This rule is March 28, 2011 without further action, unless adverse comment is received by January 27, 2011. If adverse comment is received, the Joint Board will publish a timely withdrawal of the rule in the Federal Register.

ADDRESSES: Comments should be sent to: Executive Director, Joint Board for the Enrollment of Actuaries, c/o Internal Revenue Service/Office of Professional Responsibility, SE:OPR, 1111 Constitution Avenue, NW., Washington, DC 20224. Comments will be available for inspection and copying in the IRS Freedom of Information Reading Room (Room 1621) at the above address. The telephone number for the Reading Room is (202) 622–5164 (not a toll-free number).

FOR FURTHER INFORMATION CONTACT: Earl Prater, Senior Counsel, Office of Professional Responsibility, at (202) 622–8018 (not a toll-free number).

SUPPLEMENTARY INFORMATION: The Joint Board is proposing to simplify the administration of its Privacy Act systems of records by consolidating the current nine systems into three systems of records and to revise the data elements of consolidated systems of records notices so as to ensure that they accurately reflect the jurisdictional coverage and operational requirements of the Joint Board’s regulations, which are set out at 20 CFR parts 901 through 903.

The Joint Board will publish separately in the Federal Register a notice proposing to consolidate and revise its Privacy Act systems of records. As described in the notice, the Joint Board proposes to consolidate its systems of records as follows:

JBEA–2, Charge Case Inventory Files, will be renamed “Enrolled Actuary Disciplinary Records” and will consolidate all disciplinary-related records from that system and from the following systems— JBEA–4, Enrollment Files; JBEA–8, Suspension and Termination Files; and JBEA–9, Suspension and Termination Roster.

JBEA–4, Enrollment Files, will be renamed “Enrolled Actuary Enrollment Records” and will consolidate all enrollment-related records from that system and from the following systems— JBEA–1, Application Files; JBEA–2, Charge Case Inventory Files; JBEA–3, Denied Applications; JBEA–5, Enrollment Roster; JBEA–7, General Information; JBEA–8, Suspension and Termination Files; and JBEA–9, Suspension and Termination Roster.

JBEA–6, General Correspondence File, will be renamed “Correspondence and Miscellaneous Records.” The following systems of records will be deleted upon implementation of the consolidated and revised systems:

JBEA–1, Application Files; JBEA–3, Denied Applications; JBEA–5, Enrollment Roster; JBEA–7, General Information; JBEA–8, Suspension and Termination Files; and JBEA–9, Suspension and Termination Roster.

If a system of records contains investigative material compiled for law enforcement purposes, section (k)(2) of the Privacy Act permits the head of an agency to promulgate a rule to exempt a system of records from the Privacy Act’s provisions granting individuals certain rights with respect to the records that pertain to them, including the right to review and copy the records. As permitted by section (k)(2), the Joint Board published the following documents to exempt certain systems of records:

On August 27, 1975 (40 FR 39387), the Joint Board published a proposed rule to exempt five systems of records, designating the rule as 20 CFR part 903.

On September 30, 1975 (40 FR 45113), the Joint Board published its proposed Privacy Act regulations, designating such regulations as 20 CFR part 903, and in the same publication, the Joint Board republished its proposed rule to exempt five systems of records, redesignating the exempting rule as 20 CFR 903.8.

On January 8, 1976 (41 FR 1493), the Joint Board published its final Privacy Act regulations as 20 CFR part 903 and in the same publication, the Joint Board published its final rule to exempt five systems of records, designating the exempting rule as 20 CFR 903.8.

The systems of records for which the Joint Board has claimed exemptions are listed in 20 CFR 903.8(a) as follows:

JBEA—Enrollment Files; JBEA—Application Files; JBEA—General Information; JBEA—Charge Case Inventory Files; and JBEA—Suspension and Termination Files.

This direct final rule will amend 20 CFR 903.8 as follows:

a. The exempt system currently listed as “JBEA—Charge Case Inventory Files” will be listed as “JBEA–2, Enrolled Actuary Disciplinary Records.”

b. The exempt system currently listed as “JBEA—Enrollment Files” will be listed as “JBEA–4, Enrolled Actuary Enrollment Records.”

c. The following systems will be deleted from the listing of exempt systems:

JBEA—Application Files; JBEA—General Information; and JBEA—Suspension and Termination Files.

d. Language such as “Exemption will be claimed” (§ 903.8(b)), which incorrectly implies that the Joint Board has yet to seek exemptions, and language such as the “the Joint Board seeks exemption” (§ 903.8(c)(i), (ii), (iii), (iv), (v), and (vi)), which incorrectly implies that the Joint Board’s
The revisions read as follows:

§903.8 Exemptions.

(a) Names of systems: JBEA–2, Enrolled Actuary Disciplinary Records; and JBEA–4, Enrolled Actuary Enrollment Records.

(b) Provisions from which exempted: These systems contain records described in section (k)(2) of the Privacy Act of 1974, 5 U.S.C. 552a(k)(2).

Exemptions are claimed for such records only where appropriate from the following provisions: sections (c)(3); (d); (e)(1); (e)(4)(G), (e)(4)(H), and (e)(4)(I); and (f) of 5 U.S.C. 552a.

(c) * * *

(2) * * *

(i) * * * For these reasons, the Joint Board claims exemption from the requirements of subsection (c)(3) of the Act.

(ii) * * * For these reasons, the Joint Board claims exemptions from the requirements of subsections (d)(1), (e)(4)(H), and (f)(2), (3), and (5) of the Act.

(iii) * * * Therefore, the Joint Board claims exemptions from the requirements of subsections (d)(2), (3), and (4), (e)(4)(H), and (f)(4).

(iv) * * * For these reasons, the Joint Board claims exemptions from the requirements of subsections (e)(4)(G) and (f)(1).

(v) * * * For these reasons, the Joint Board claims exemption from the requirements of subsection (e)(1).

(vi) * * * For these reasons, the Joint Board claims exemption from the requirements of subsection (e)(4)(I).

Dated: November 4, 2010.

Carolyn E. Zimmerman,
Chair, Joint Board for the Enrollment of Actuaries.
[FR Doc. 2010–32165 Filed 12–27–10; 8:45 am]
BILLING CODE 4830–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 522

[Docket No. FDA–2010–N–0002]

New Animal Drugs; Deslorelin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an original new animal drug application (NADA) filed by Thorn Bioscience LLC. The NADA provides for the use of deslorelin acetate injectable suspension in mares for inducing ovulation.

DATES: This rule is effective December 28, 2010.

FOR FURTHER INFORMATION CONTACT: Amy L. Omer, Center for Veterinary Medicine (HFV–114), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–276–8336, e-mail: amy.omer@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Thorn Bioscience LLC, 1044 East Chestnut St., Louisville, KY 40204, filed NADA 141–319 that provides for use of SUCROMATE Equine (deslorelin acetate), an injectable suspension, in mares for inducing ovulation. The NADA is approved as of November 5, 2010, and the regulations are amended in 21 CFR 522.533 to reflect the approval.

In addition, Thorn Bioscience LLC has not been previously listed in the animal drug regulations as a sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to add entries for this firm.

In accordance with the freedom of information provisions of 21 CFR parts 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The Agency has determined under 21 CFR 25.33 that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)[F](ii)), this approval qualifies for 3 years of marketing exclusivity beginning on the date of approval.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.